va glp 1 coverage Pentagon Drops of GLP-1 Weight Loss Meds for Medicare-Eligible Retirees Perspectives from employers on the

And as GLP-1-based medications have become more widely used, I wanted to better understand whether these therapies, when they're prescribed for obesity or diabetes, might also affect arthritis and cardiovascular risk in our patients

Nat Commun 10 , 924 (2019)

But for many Americans, the issue taps into something deeper years of frustration with a system they say feels stacked against them, where prices are hard to track and its not always clear if theyre getting a fair deal

How These Results Compare to Other Weight Loss Medicines Retatrutide's 24.2% mean weight loss at 48 weeks exceeds phase 3 data for semaglutide 2.4 mg (~14.9% at 68 weeks) and is comparable to tirzepatide 15 mg (~22.5% at 72 weeks), though no direct head-to-head trials have been conducted

While there is mixed evidence regarding whether GLP-1RA increase risk for acute pancreatitis and they are associated with thyroid tumors in animals, prescribers should consider these possible adverse effects in patients at elevated risk for either outcome

disorder : (in medicine) A condition where the body does not work appropriately, leading to what might be viewed as an illness